BBI Solutions coronavirus reagents

In the midst of the global coronavirus pandemic, BBI Solutions has partnered with The Native Antigen Company to deliver virus-specific antigens. These coronavirus reagents are in addition to the company’s complementary product portfolio including enzymes, gold nanoparticles and secondary antibodies so that BBI can assist in the development of immunological coronavirus diagnostic kits.

BBI Solutions is offering recombinant SARS-CoV spike 1 and spike 2 glycoproteins and nucleoprotein for the 2019 novel coronavirus (SARS-CoV-2, COVID-19) and spike 1 glycoprotein for the related SARS coronavirus. The antigens are produced in The Native Antigen Company’s proprietary expression systems, including its VirtuE (HEK293) expression system, to ensure glycosylation and proper folding. All reagents are suitable to support vaccine R&D, diagnostic development or basic research.

The COVID-19 antigens and specific antibodies are critical tools for the development of rapid immunological testing kits alongside ancillary reagents and raw materials essential for the method development including secondary antibodies, enzymes and gold nanoparticles that enable lateral flow-based methods.